{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:52:56Z","timestamp":1791273176541,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109549","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:23:54Z","timestamp":1784820234000},"page":"109549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of immunotherapy on overall survival and healthcare costs in advanced\/metastatic lung cancer: A real-world study in France"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-1664","authenticated-orcid":false,"given":"Adrien","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Foix-Colonier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5726-0043","authenticated-orcid":false,"given":"Jo\u00ebl","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Foulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Valentine Laizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil-Jonathan","family":"Jewiti-Rigondza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6655-7586","authenticated-orcid":false,"given":"Alaeddine","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Nacef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Ezzalfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109549_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"key":"10.1016\/j.lungcan.2026.109549_b0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0015","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109549_b0025","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01605","article-title":"Five-Year Outcomes from the Randomized, phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in previously Treated Non\u2013Small-Cell Lung Cancer","author":"Borghaei","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109549_b0045","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109549_b0050","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and platinum for previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109549_b0055","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.21037\/tlcr-23-271","article-title":"KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer","volume":"12","author":"Chen","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2026.109549_b0060","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and platinum in Nonsquamous Non\u2013Small-Cell Lung Cancer: 5-Year Outcomes from the phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109549_b0065","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1\u2013Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0070","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jtho.2025.03.033","article-title":"Cemiplimab Monotherapy for First-Line Treatment of patients with Advanced NSCLC with PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1","volume":"20","author":"Kilickap","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109549_b0075","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1200\/JCO.2024.42.16_suppl.11075","article-title":"Trends in prices of checkpoint inhibitors in the US, 2016-2023","volume":"42","author":"Paul","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2026.109549_b0080","doi-asserted-by":"crossref","first-page":"S936","DOI":"10.1016\/j.annonc.2024.08.1597","article-title":"1535O cost and value of EMA-registered checkpoint inhibitors for solid tumours in the Netherlands","volume":"35","author":"Huisman","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109549_b0085","doi-asserted-by":"crossref","unstructured":"Tay-Teo K, Trapani D, Sengar M, et al. Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer. eClinicalMedicine 2025;84:103261. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103261.","DOI":"10.1016\/j.eclinm.2025.103261"},{"key":"10.1016\/j.lungcan.2026.109549_b0090","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/s41598-021-85696-3","article-title":"Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands","volume":"11","author":"Cramer-van Der Welle","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109549_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100970","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study","volume":"43","author":"Rousseau","year":"2024","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.1016\/j.lungcan.2026.109549_b0100","doi-asserted-by":"crossref","first-page":"00174","DOI":"10.1183\/23120541.00174-2019","article-title":"A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer","volume":"6","author":"Legoupil","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.lungcan.2026.109549_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100353","article-title":"IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer","volume":"7","author":"Molinier","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109549_b0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2022.08.001","article-title":"Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany","volume":"172","author":"Griesinger","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109549_b0115","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/cancers17223630","article-title":"Real-World Comparative Study of Atezolizumab-based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer","volume":"17","author":"Ohiwa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109549_b0120","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/1759-7714.15069","article-title":"Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: results from a retrospective chart review of patients with advanced\/metastatic non-small cell lung cancer in the EU5","volume":"14","author":"Slowley","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lungcan.2026.109549_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102031","article-title":"Real world data in the era of Immune Checkpoint Inhibitors (ICIs): increasing evidence and future applications in lung cancer","volume":"87","author":"Pasello","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109549_b0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40273-025-01514-y","article-title":"Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: a Case Study of Pembrolizumab","volume":"43","author":"Zemplenyi","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.lungcan.2026.109549_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114231","article-title":"Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012\u20132021)","volume":"208","author":"De Nijs","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109549_b0140","article-title":"Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system","volume":"2025","author":"Chouaid","year":"2013","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.lungcan.2026.109549_b0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.18332\/tid\/149477","article-title":"Burden of current and past smoking across 28 European countries in 2017: a cross-sectional analysis","volume":"20","author":"Teshima","year":"2022","journal-title":"Tob. Induc. Dis."},{"key":"10.1016\/j.lungcan.2026.109549_b0150","article-title":"Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible patients with Metastatic NSCLC in the German prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)","volume":"5","author":"Griesinger","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109549_b0155","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world Data for Clinical evidence Generation in Oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.lungcan.2026.109549_b0160","doi-asserted-by":"crossref","unstructured":"Debieuvre D, Falchero L, Molinier O, et al. Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. NEJM Evidence 2025;4:EVIDoa2400443. doi: 10.1056\/EVIDoa2400443.","DOI":"10.1056\/EVIDoa2400443"},{"key":"10.1016\/j.lungcan.2026.109549_b0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10198-025-01827-x","article-title":"Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1\u2009\u2265\u200950% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis","volume":"27","author":"Liu","year":"2026","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.lungcan.2026.109549_b0170","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109549_b0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:25:48Z","timestamp":1791271548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0169500226006100"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109549","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of immunotherapy on overall survival and healthcare costs in advanced\/metastatic lung cancer: A real-world study in France","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109549"}}